Introduction {#s1}
============

Globally, *Staphylococcus aureus* and *Pseudomonas aeruginosa* (PA) are two major opportunistic pathogens that cause community-acquired and nosocomial infections. *S. aureus* and PA are the most prevalent pathogens that colonize structurally abnormal airways such as those in cystic fibrosis (CF) and other chronic obstructive lung diseases (Lyczak et al., [@B37]; Hubert et al., [@B27]). In addition, they are frequently found together in chronic wound infections (Gjødsbøl et al., [@B21]; Fazli et al., [@B16]). *S. aureus* and PA cause biofilm-related infections, and methicillin-resistant *S. aureus* (MRSA) has emerged as a clinically relevant pathogen because of its resistance to antibiotics and its ability to form biofilms (Chopra et al., [@B8]). Bacteria within biofilms are difficult to eradicate because being encased in a polymer matrix decreases their susceptibility to antimicrobials and immune defenses; this inherent antimicrobial resistance provides added resistance to antimicrobial therapy and host defense. In addition, during infection, the bacteria that originate in biofilms disperse as planktonic cells, which results in spread to secondary sites and progression of the infection (Hall-Stoodley and Stoodley, [@B23]; Lister and Horswill, [@B35]). MRSA and PA have been detected in biofilm-related infections such as chronic suppurative otitis media (CSOM) and chronic middle ear infections (Jung et al., [@B28]; Kim et al., [@B31]). *S. aureus* and PA have been isolated from upper respiratory tract infections including several chronic diseases such as chronic otitis media, cholesteatoma, chronic adenoiditis, chronic sinusitis, post-operative trampansomay, and nasal polyposis (Post et al., [@B51]; Bendouah et al., [@B2]; Boase et al., [@B4]). In chronic rhinosinusitis (CRS) patients, multi-species biofilms have been associated with enhanced mucosal inflammation, more severe osteitis, higher incidence of recurrent infection (Li et al., [@B33]; Dong et al., [@B14]), and postoperative outcomes (Singhal et al., [@B56]), and post-surgery progression (Bendouah et al., [@B2]). Furthermore, *S. aureus* and PA have been isolated from multi-species biofilms that are frequently found on indwelling medical devices such as prostheses, stents, implants, catheters, and endotracheal tube (Percival et al., [@B50]). Although the effect of poly-microbial infections of *S. aureus* and PA has not been well studied, some studies suggested that such poly-microbial infections are more virulent than single species infections (Hendricks et al., [@B24]; Pastar et al., [@B48]). Voggu et al. ([@B61]) reported that *in vitro* interactions between *S. aureus* and PA are competitive and result in PA eradicating *S. aureus* (Voggu et al., [@B61]). However, it has been reported that during polymicrobial colonization of PA and *S. aureus*, PA does not completely inhibit the colonization of *S. aureus*; rather, *S. aureus* employs numerous defense strategies for its survival in the same ecological niche and grows as a small-colony variant (SCV) (Biswas et al., [@B3]). As a result of the competitive interactions between *S. aureus* and PA, an altered colony morphology strains called small colony variants (SCVs) emerges. Those SCVs are more persistent and more antibiotic-resistant strains than normal *S. aureus* (Nair et al., [@B44]).

Multi-species biofilm infections have important implications for management because this association will modify the clinical course of the disease, affecting the selection of antimicrobial therapy and the anticipated response to treatment. However, despite the gravity of these multi-species infections, their pathogenesis remains largely unknown. Therefore, in this study, we investigated *S. aureus* and PA multi-species biofilm communities *in vitro*, and assessed their interaction with the host during *in vivo* colonization using an otitis media rat model.

Materials and methods {#s2}
=====================

Ethics statement
----------------

All animal experiments were performed in accordance with the guidelines of the Animal Research Committee, Korea University College of Medicine, Seoul, South Korea. The animal experiment protocol was approved by the Institute Review Board of Korea University, Guro Hospital, Seoul, South Korea (Permit Number, KOREA 2016-0019).

Bacterial strain and culture medium
-----------------------------------

Methicillin resistant *S. aureus* (MRSA) was purchased from the Culture Collection of Antimicrobial Resistant Microbes (CCARM 3903), Seoul, Korea. *P. aeruginosa* (ATCC 27853) was obtained from the American Type Culture Collection (Manassas, VA). The selective medium for MRSA was oxacillin resistance screening agar base (ORSAB) and *Pseudomonas*-specific medium was Pseudomonas agar base (PAB), and was purchased from Oxoid limited (Hampshire, UK). 2-n-heptyl-4-hydroxyquinoline-N-oxide (HQNO) was purchased from Santa Cruz Biotechnology (Dallas, Texas, USA).

*In vitro* single species or multispecies biofilm growth of MRSA or PA
----------------------------------------------------------------------

Single- or multi-species *in vitro* biofilm growth of MRSA and PA was established in 24-well (flat-bottom) polystyrene tissue culture plates (BD Falcon, Sparks, MD, USA) using a static model and a previously described procedure (Christensen et al., [@B9]; Yadav et al., [@B66]). The biofilm biomass was quantified using a crystal violet (CV) microtiter plate assay, and the bacterial loads within biofilms were enumerated by colony forming unit (CFU) counts. MRSA or PA cell suspensions (1 × 10^7^), individually or in combination in TSB media, were inoculated (1 mL) in 24-well polystyrene plates. The plates were incubated at 37°C for 24 h. After incubation, medium was discarded, and plates were gently washed with 1 mL sterile water. Thereafter, plates were air-dried and stained with 200 μL CV (0.1%) for 15 min. Excess stain was decanted, and plates were washed three times with sterile distilled water. The biofilm was dissolved in 1 mL (95%) ethanol and the optical density (OD) at 570 nm was measured in an automatic spectrophotometer. All experiments were performed in triplicate and the average was calculated. The experiments were repeated three times.

Alternatively, MRSA, PA, or combinations of both species were grown in TSB medium under the same conditions. CFUs were counted to quantify the number of viable cells growing in the biofilms. Biofilms were dissolved with sonication at 50 W for 10 s, serially diluted, and plated on selective medium, specifically ORSAB or PAB with CN supplement, to determine CFU-values.

To characterize the biofilm matrix, 24-h pre-established biofilms of MRSA or PA were treated with 10 mM sodium metaperiodate (Sigma, St. Louis, MO, USA), 100 μg/mL DNase I (Roche, Mannheim, Germany), 100 μg/mL alginate lyase (sigma), and 100 μg/mL proteinase K (sigma) by procedure previously described (Gutiérrez et al., [@B22]). The control biofilms were treated with respective buffer. The biofilms biomass was quantified as described above.

Biofilm growth of SCVs of MRSA
------------------------------

*S. aureus* forms SCVs in the presence of HQNO produced by PA (Mitchell et al., [@B43]). To evaluate biofilm formation capability of SCVs of MRSA (3903), biofilms were grown with (20 μg/mL) HQNO, whereas the control biofilm was grown with DMSO supplementation. Biofilm biomass was quantified using a CV-microtiter plate assay as described above. The morphological variations in SCV biofilms grown with HQNO were examined using a scanning electron microscope (SEM).

*In vivo* single species or multispecies colonization of MRSA or PA in the rat middle ear
-----------------------------------------------------------------------------------------

*In vivo* single species or multispecies colonization by MRSA or PA was assessed using a previously described otitis media (OM) model (Yadav et al., [@B65], [@B67], [@B64]). Forty pathogen-free Sprague-Dawley rats weighing 150--200 g were obtained from Koatech (Pyeongtaek, South Korea). Before the experiment, all animals were examined for abnormalities in the middle ear and were housed in an infection-free zone for 2 weeks. The rats were divided into four experimental groups. Group 1 included rats inoculated with MRSA only (*n* = 11); Group 2 was rats inoculated with PA only (*n* = 11); Group 3 included rats inoculated with a mixed culture of MRSA + PA (*n* = 11); and Group 4 was rats inoculated with media only (vehicle control; *n* = 7). The bacterial cell suspensions were prepared in TSB medium. Cell suspension (50 μL) containing 1 × 10^7^ CFU of either single species MRSA, PA, or mixed culture of the *two* species was injected into the middle ear cavity through the tympanic membrane of the right ear using a tuberculin syringe and a 27-gauge needle. The animals were euthanized using a 1:1 combination of nitrous oxide and oxygen. One week after inoculation, the rats were sacrificed using carbon dioxide inhalation, and the bulla was aseptically acquired. The tympanic membrane was removed, and the ears were irrigated to remove planktonic bacteria. The bullae from each group were dissected and cleaned, and the middle ear was visualized and photographed. The bullae were homogenized, serially diluted, and plated on selective plates to obtain CFU counts. For SEM analysis, the bullae were preserved in SEM solution.

Visualization of *in-vitro* biofilms and *in-vivo* colonization of MRSA or PA single species or multi-species using SEM
-----------------------------------------------------------------------------------------------------------------------

MRSA or PA single species or multispecies *in vitro* biofilms grown in 24-well tissue culture plates for 24 h were analyzed by SEM. After a 24-h incubation, the medium with planktonic cells were discarded, and the plates were gently washed twice with sterile PBS. Samples were pre-fixed by immersion in 2% glutaraldehyde and 2.5% paraformaldehyde solution, and post-fixed for 2 h in 1% osmic acid dissolved in PBS. Samples were treated with a graded series of ethanol and *t*-butyl alcohol. The samples were freeze-dried in a freeze dryer (ES-2030 Hitachi, Tokyo, Japan), followed by platinum coating using an IB-5 ion coater (Eiko, Kanagawa, Japan), and specimens were visualized using a S-4700 field emission scanning electron microscope (Hitachi).

Similarly, for SEM analysis of *in vivo* colonization by MRSA or PA, the rat bullae from representative groups were dissected and cleaned of unwanted tissue, and the middle ear was carefully opened. The bullae were preserved in glutaraldehyde and paraformaldehyde solution. The rest of the protocol (pre-fix, post-fix, dehydration, etc.) was the same as that described previously for *in vitro* biofilms.

Total RNA extraction and transcriptome sequencing using rat mucosa colonized with single or multi-species of MRSA or PA
-----------------------------------------------------------------------------------------------------------------------

Rats from representative groups were sacrificed as described above, and the bullae were acquired. Bullae were immediately dissected, and the middle ear was exposed and preserved in RNAlater (Qiagen, Hilden, Germany). The mucosal membrane of the bullae preserved in RNAlater solution was carefully scraped and preserved in fresh RNAlater solution until RNA extraction. Total RNA was isolated using a Qiagen RNeasy kit (Qiagen, Hilden, Germany) in accordance with the manufacturer\'s instructions. RNA was quantified using a nano-drop, and the RNA quality was assessed by analysis of rRNA band integrity using an Agilent RNA 6000 Nano kit (Agilent Technologies, Palo Alto, CA, USA). Ahead of cDNA library construction, 2 μg of total RNA and magnetic beads with Oligo (dT) were used to enrich poly(A)-containing mRNA. Subsequently, the purified mRNA was disrupted into short fragments, and double-stranded cDNA was immediately synthesized. The cDNA was subjected to end-repair and poly(A) addition, and was connected with sequencing adapters using the TruSeq RNA sample prep kit (Illumina, CA, USA). Suitable fragments that were automatically purified using a BluePippin 2% agarose gel cassette (Sage Science, MA, USA) were selected as templates for PCR amplification. The final library sizes and qualities were evaluated electrophoretically using an Agilent high sensitivity DNA kit (Agilent Technologies, CA, USA) and the fragment was determined to be between 350 and 450 bp. Subsequently, the library was sequenced using an Illumina HiSeq2500 sequencer (Illumina, CA, USA).

Low quality reads were filtered according to the following criteria; reads containing more than 10% of skipped bases (marked as "N"s), reads containing more than 40% of bases with quality scores \<20, and reads with average quality scores \<20. The entire filtering process was performed using the in-house scripts. Filtered reads were mapped to the human reference genome (Ensembl release 72) (Flicek et al., [@B19]) using aligner STAR v.2.3.0e (Dobin et al., [@B13]).

Gene expression levels were measured with Cufflinks v2.1.1 (Trapnell et al., [@B59]) using the gene annotation database of Ensembl release 72. The non-coding gene region was removed with the mask option. To improve the accuracy of measurement, multi-read-correction and fragbias-correct options were applied, whereas all other options were set to default values. For differential expression analysis, gene level count data were generated using the HT Seq-count v0.5.4p3 (Anders et al., [@B1]) tool with the option "-m intersection-nonempty" and -r option, considering paired-end sequences.

Based on the calculated read count data, differentially expressed genes (DEG) were identified using the R package TCC (Sun et al., [@B57]). The TCC package applies robust normalization strategies to compare tag count data. Normalization factors were calculated using the iterative DEGES/edgeR method. Q-values were calculated based on the *p*-value using the p.adjust function of the R package with default parameter settings. DEGs were identified based on a q-value threshold \< 0.05. Gene ontology (GO) and KEGG pathway analysis of the DEGs were performed using STRING version 10.

Quantification of gene expression using real-time RT-PCR
--------------------------------------------------------

RNA-sequencing gene expression results were confirmed by real-time RT-PCR. Eighteen DEGs, and one house-keeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were analyzed by real-time RT-PCR. The gene sequences were downloaded from the NCBI gene bank, and primers were designed using primer express software (Table [1](#T1){ref-type="table"}). cDNA synthesis was performed using a PrimeScript first strand cDNA synthesis kit according to the manufacturer\'s instructions (TaKaRa Bio Inc., Kusatsu, Japan). The amplification reaction was performed in an ABI Prism 7300 real-time PCR system (Applied Biosystems, Foster, CA, USA) in a total volume of 20 μL. The reaction mixture consisted of 10 μL of 2 × SYBR Green PCR Master Mix (Roche Applied Science, Indianapolis, IN, USA), 2.5 pmol of each forward and reverse primer, and 4 μL cDNA. The PCR reaction mixture was incubated as follows: initial denaturation at 95°C for 10 min, followed by 45 cycles of DNA denaturation at 95°C for 15 s, primer annealing and extension at 56°C for 1 min, and a final extension step at 72°C for 5 min. A control reaction without reverse transcriptase was included in each real-time RT-PCR experiment to check for cDNA contamination with genomic DNA. The relative quantification of gene expression in rat mucosa inoculated with *S. aureus*, PA, or mixed culture, with respect to the type of media, was performed using the 2^−ΔΔCT^ method (Livak and Schmittgen, [@B36]), and the gene expression values were normalized to those of the housekeeping gene, GAPDH.

###### 

**List of primers used in this study**.

  **Serial number**   **Gene name**   **Sequence**                           **Base pairs**   **Amplicon size**
  ------------------- --------------- -------------------------------------- ---------------- -------------------
  1                   *KERA*          F: CCG TCG AGG GGT TTT GAT GT          20               246
                                      R: CAT CGG GAT TGG TGG CTT GA          20               
  2                   *GPD1*          F: AAC AGG TGC TGA CAT CCT GG          20               254
                                      R: AGC CAA TGG TCG TCT CAC AG          20               
  3                   *ACTA1*         F: CTC TTG TGT GTG ACA ACG GC          20               124
                                      R: CCC ATA CCG ACC ATG ACA CC          20               
  4                   *EEF1A2*        F: TCG GAT CCT CGT TAC GCC G           19               195
                                      R: GCC GGC GGT TTT ATC TCT CT          20               
  5                   *HRC*           F: CTT CCA GGA GCC ATG GTT GT          20               138
                                      R: CCA GGG ATA CCT GCG TTG TT          20               
  6                   *FOXD1*         F: GGT ACT CTG CAC CAA GGG AC          20               130
                                      R: CCC ATC CGT AGA AAG GAG CC          20               
  7                   *MYH1*          F: AGT TGC ATC CCT AAA GGC AGA         21               148
                                      R: GGC TTG TTC TGA GCC TCG AT          20               
  8                   *SYNPO2L*       F: GGG TAC CAG CAC CTC AAC TT          20               233
                                      R: TAA GAG CTG GTC CCT CTC CC          20               
  9                   *TNMD*          F: GTC CCA CAA GTG AAG GTG GA          20               148
                                      R: TGC CTC GAC GGC AGT AAA TA          20               
  10                  *MYOM2*         F: GGT ACT CCT CAT CTT TCT GGG AA      23               134
                                      R: TCG ATG CAT ATC GGT CCA GG          20               
  11                  *RPS9*          F: CGT TTC TCT TTG TCA CGG GC          20               192
                                      R: CCT CCA CAC CTC ACG TTT GT          20               
  12                  *MMP12*         F: CTC CCA TGA ACG AGA GCG AA          20               170
                                      R: GGT GTC CAG TTG CCC AGT TA          20               
  13                  *ITGB2*         F: TTG TCA ACA CCC ATC CCG AG          20               215
                                      R: AAT TTC CTC CGG ACA GGC AG          20               
  14                  *CST7*          F: GCA TAC ACC TCA GAT TTT TGT TCC A   25               235
                                      R:TAG TTC GGC CGA TTT CCA CC           20               
  15                  *SCTR*          F: GTC ATT CGA GGG CCT GTG AT          20               197
                                      R: GGG GAG AAG GCG AAG ACA AT          20               
  16                  *APOC1*         F: CAT AGT GGT GGG AGG TGG TG          20               103
                                      R: AGG AAG TGC GAT GAA GAG CC          20               
  17                  *CD69*          F: GCGATATGCTGGTGGACTGA                20               111
                                      R: GACCCTGTCACGTTGAACCA                20               
  18                  *CCNO*          F: CCAGTCGTTGCAGCCCATTA                20               261
                                      R: ACCTCTCGGCAAGTCAAAGG                20               

Statistical analysis
--------------------

Values were calculated as the mean of individual experiments that were performed in triplicate, and compared to those of the control groups. Differences between mean values were assessed using a Student\'s *t*-test. Statistical significance was set at *p* \< 0.05.

Results {#s3}
=======

*In vitro* single species or multispecies biofilm growth of MRSA or PA
----------------------------------------------------------------------

To assess the growth of MRSA and PA in single and multi-species biofilms, *in vitro* single and multi-species biofilms were grown on polystyrene plates that allowed for bacterial attachment and biofilm formation. The biofilms were quantified using a CV-microtiter plate assay after removing planktonic cells. The CV-microtiter plate assay detected significantly (*p* \< 0.05) increased biofilm biomass in multi-species biofilms of MRSA and PA, compared to single species biofilms of either MRSA or PA (Figure [1A](#F1){ref-type="fig"}). The OD~570~-values of single species biofilms of MRSA and PA were 0.7 and 1.8, respectively; however, that of the multi-species biofilm was 2.0. These results indicated that total biomass of multi-species biofilms were higher than that of single species biofilms, which might be because of the accumulation of extracellular polysaccharide (EPS) and cells from both species. Thus, both species contributed to increased biofilm biomass.

![**Quantification of single- and multi-species *in vitro* biofilms of methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa* (PA). (A)** Quantification of single-species and multi-species biofilms of MRSA or PA using crystal violet microtiter plate assays. **(B)** Colony forming unit (CFU) counts of bacteria within single- and multi-species biofilms of MRSA or PA. **(C)** Eradication of pre-established MRSA biofilms with sodium metaperiodate (SM), DNase I and proteinase K with respect to control (untreated). **(D)** Eradication of PA pre-established biofilms with alginate lyase, DNase I, and proteinase K. The error bars represent the standard deviation from the mean value. The results were compared using a Student\'s *t*-test (^\*^*p* \< 0.05).](fcimb-07-00125-g0001){#F1}

To further evaluate the viable bacteria in single or multi-species biofilms, CFUs were enumerated. The CFU counts showed significantly higher numbers of bacteria in single species biofilms than in multi-species biofilms of either MRSA or PA (Figure [1B](#F1){ref-type="fig"}). In single species biofilms, the CFU counts for MRSA and PA were 1 × 10^8^ and 4 × 10^9^, respectively. In multi-species biofilms, PA inhibited the growth of MRSA. The CFU counts of MRSA and PA in multi-species biofilms were 1 × 10^6^ and 8 × 10^8^, respectively. The CFU counts for PA were significantly (*p* \< 0.05, approximately 2.6 log values) higher than those of MRSA. These results indicated that PA and MRSA could exist together in multi-species *in vitro* biofilms. However, the decreased CFU counts for MRSA indicated that PA partially inhibited the growth of MRSA in multi-species biofilms.

The treatment of pre-established biofilm of MRSA with DNase I and Proteinase K significantly (*p* \< 0.05) decreased biofilm biomass in compare to control biofilms (Figure [1C](#F1){ref-type="fig"}). However, no effect of sodium metaperiodate was detected. These results indicate that MRSA biofilms contains e-DNA and proteins, and the MRSA produce *ica*- independent biofilms. Previous studies reported no effect of sodium metaperiodate on MRSA biofilms (Fitzpatrick et al., [@B18]). Treatment of PA biofilms with DNase I and proteinase K significantly (*p* \< 0.05) reduced biofilms biomass. However, very low biofilm eradication activity of alginate lyase was detected on pre-established biofilms of PA (Figure [1D](#F1){ref-type="fig"}). PA is known to produces at least three types of exopolysaccharides. The mucoid PA strains predominantly produce alginate exopolysaccharide (Hentzer et al., [@B25]), and non-mucoid strains produce the Pel and Psl polysaccharides for biofilm formation (Wozniak et al., [@B63]). ATCC 27853 is a standard non-mucoid strain (Li et al., [@B34]). These results indicate that PA (ATCC 27853) biofilms contains DNA and proteins along with polysaccharides primarily the Pel and Psl.

MRSA or PA single-species or multi-species *in vitro* biofilms were analyzed using SEM. SEM analysis revealed that single-species biofilms were compact, and cells were connected to the bottom of the plate and to each other (Figures [2A,B](#F2){ref-type="fig"}). The multi-species biofilms were also compact, and the bacteria were interconnected to each other and to the surface. In multi-species biofilms, the biofilm debris or may be EPS was visible that were not visible in single species biofilms of either MRSA or PA (Figure [2C](#F2){ref-type="fig"}). As expected in multi-species biofilms, fewer *S. aureus* bacteria were visible than PA, indicating that PA partially inhibited MRSA growth in the biofilm state.

![**Scanning electron microscope (SEM) images of *in vitro* biofilms of single or multi-species methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa* (PA). (A)** Representative SEM image of MRSA single species biofilms. **(B)** Representative SEM images of PA single species biofilms. **(C)** Representative SEM images of multi-species biofilms of MRSA and PA.](fcimb-07-00125-g0002){#F2}

SCVs of MRSA enhance biofilm formation
--------------------------------------

The *in vitro* biofilm formation ability of MRSA 3903 SCVs was evaluated by culturing biofilms in the presence or absence of HQNO. CV-microtiter plate assay results showed no significant decrease in MRSA biofilm biomass in the presence of 20 μg HQNO (Figure [3](#F3){ref-type="fig"}). SEM images revealed no significant difference between SCV biofilms and phenotypically normal MRSA biofilms (Figure [4](#F4){ref-type="fig"}). These results indicate that MRSA 3903 could form SCVs, and that MRSA could exist in multi-species biofilms with PA.

![***In vitro*** **biofilm growth of methicillin-resistant *Staphylococcus aureus* (MRSA) small colony variant**. *In vitro* biofilm growth of MRSA supplemented with HQNO (20 μg/mL) or without HQNO. The biofilm biomass was detected by a crystal violet microtiter plate assay. Error bars represent standard deviation from the mean value.](fcimb-07-00125-g0003){#F3}

![**Scanning electron microscopic (SEM) image of methicillin-resistant *Staphylococcus aureus* (MRSA) biofilms grown with and without HQNO**. Images **(A--C)** are representative SEM images of control biofilms (DMSO). **(D--F)** Representative SEM images of biofilm growth with 20 μg/ml HQNO. Scale bar = 5, 10, 50 μm.](fcimb-07-00125-g0004){#F4}

*In vivo* colonization of MRSA and PA alone or together in the rat middle ear
-----------------------------------------------------------------------------

Rats were sacrificed 1 week after inoculation, and bullae were acquired. The representative rat bullae were dissected and photographed (Figures [5A--D](#F5){ref-type="fig"}). The rat bullae inoculated with media only (vehicle control) were clear with no sign of mucosal inflammation or bacterial colonization (Figure [5A](#F5){ref-type="fig"}). However, the rat bullae inoculated with MRSA or PA alone or together were filled with a sticky fluid and showed signs of bacterial colonization. The mucosa was thick, swollen, and showed signs of severe inflammation (Figures [5B--D](#F5){ref-type="fig"}). The mean CFU counts for the rat bullae inoculated with MRSA and PA alone were 2.63 × 10^5^ (*SD* = 1.07 × 10^5^) and 4.50 × 10^5^ (*SD* = 7.07 × 10^4^), respectively. A higher number of PA CFUs, compared to MRSA CFUs, was recovered from rat bullae inoculated with either MRSA or PA alone; however, this difference was not significant. The CFU counts for MRSA and PA in the rat bullae inoculated with both species were 1.34 × 10^5^ (*SD* = 1.1 × 10^5^) and 1.10 × 10^5^ (*SD* = 7.3 × 10^4^), respectively (Figure [5E](#F5){ref-type="fig"}). No significant difference in CFU counts between MRSA and PA were detected in multi-species-inoculated rat bullae. However, the CFU counts for PA alone were significantly high than those of PA in multi-species inoculations.

![**Quantification of methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa* (PA) in the rat middle ear. (A)** Digital image of rat bulla inoculated with media only. **(B)** Digital image of rat bulla inoculated with MRSA only. **(C)** Digital images of rat bulla inoculated with PA only. **(D)** Digital image of rat bulla inoculated with multi-species (MRSA + PA). **(E)** Colony forming unit (CFU) counts for rat bullae inoculated with single or multi-species MRSA or PA in the rat middle ear.](fcimb-07-00125-g0005){#F5}

Visualization of *in vivo* colonization of MRSA and PA alone or in combination
------------------------------------------------------------------------------

SEM images of rat middle ears inoculated with MRSA, PA, MRSA + PA, or control inoculum are shown in Figure [6](#F6){ref-type="fig"}. In the control middle ear, the ciliated epithelium in the hypotympanum area and Eustachian tube orifice were intact (Figures [6A--C](#F6){ref-type="fig"}). In the MRSA, PA, or MRSA + PA treated groups, the entire middle ear was covered with cell debris or biofilm EPS. The tips of the cilia were invisible due to the deposition of cell debris (Figures [6D--L](#F6){ref-type="fig"}).

![**Scanning electron microscope (SEM) images of bullae inoculated with methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa* (PA) as a single or multi-species inoculum. (A--C)** Representative SEM images of no procedure control. **(D--F)** Representative SEM images of rat bullae inoculated with SA only. **(G--I)** Representative SEM images of rat bullae inoculated with PA only. **(J--L)** Representative SEM images of rat bullae inoculated with a mixed culture of MRSA and PA.](fcimb-07-00125-g0006){#F6}

Transcriptome sequencing of rat mucosa inoculated with MRSA, PA, or a combination of the two
--------------------------------------------------------------------------------------------

Total raw data reads in all samples ranged from 50 to 65 million, with an average of approximately 55 million raw reads per sample. The average mRNA insert size detected by sequencing and mapping was 159 bp. The uniquely mapped reads ranged between \~50 and 55 million; there were \~5 million mapped reads and \~6 million unmapped reads (Figure [7A](#F7){ref-type="fig"}). There were \~58 million total reads, 55 million genome reads, and 43 million gene reads (Figure [7B](#F7){ref-type="fig"}). The gene reads were \~20 K, known genes were \~5 K, known plus new isoforms were \~12 K, and novel genes were \~5 K (Figure [7C](#F7){ref-type="fig"}). A total of 1797 genes were significantly (*p* \< 0.05) differentially expressed in all three treatments with respect to the control (media). Among them, 973 were upregulated \> 1-fold and 824 were downregulated \> 1-fold.

![**Overview and summary of raw data analysis after transcriptome sequencing to assess gene expression in rat middle ear mucosae inoculated with methicillin-resistant *Staphylococcus aureus* (MRSA) or *Pseudomonas aeruginosa* (PA) as a single species or multi-species inoculum. (A)** Graphical representation of uniquely mapped, mapped, and unmapped reads. **(B)** Graphical representation of total reads, gene reads, and genome reads. **(C)** Graphical representation of novel genes, known genes, and all genes.](fcimb-07-00125-g0007){#F7}

Differential gene expression
----------------------------

A total of 360, 634, and 504 genes were significantly (*p* \< 0.05) upregulated in multi-species, MRSA and PA, colonized rat middle ear mucosae (Figure [8A](#F8){ref-type="fig"}). Among 360 upregulated genes in multi-species-colonized rat mucosae, 113 (31%) were similar to those of MRSA, and 22 (6.1%) were similar to those of PA. The three treatments shared 163 genes whose expression was upregulated. Moreover, 62 genes were exclusively upregulated during multi-species colonization. Among them, the 42 genes upregulated by ≥1.5-fold and encoding proteins of known functions are shown in Table [2](#T2){ref-type="table"}. A total of 580, 401, and 481 genes were significantly (*p* \< 0.05) downregulated in multi-species-, MRSA-, and PA-colonized rat middle ear mucosae (Figure [8B](#F8){ref-type="fig"}). Among the 580 downregulated genes after multi-species colonization, 75 genes (12.9%) were similar to those associated with MRSA, and 168 (28.9%) genes were similar to those associated with PA. Among 160 genes exclusively downregulated after multi-species colonization, 88 genes that were downregulated by ≥1.5-fold and encoding known proteins are shown in Table [3](#T3){ref-type="table"}. The gene ontology (GO) of upregulated and downregulated genes in multi-species inoculated rat mucosae is shown in Figures [9A,B](#F9){ref-type="fig"}. The GO analysis of 42 protein-encoding genes that were upregulated (≥1.5-fold) after multi-species colonization revealed that genes involved in defense, immune response, inflammatory response, and developmental process were exclusively upregulated after multi-species inoculation (Figure [9A](#F9){ref-type="fig"}). The GO analysis of 88 protein-encoding genes that were downregulated (≥1.5-fold) revealed that genes that are involved in nervous system signaling, development and transmission, regulation of cell growth and development, anatomical and system development, and cell differentiation were significantly downregulated after multi-species inoculation (Figure [9B](#F9){ref-type="fig"}). Based on KEGG pathway analysis of upregulated genes after multi-species inoculation, genes involved in phagosome, antigen processing and presentation, influenza A infection, *Staphylococcus* infection, herpes virus infection, toxoplasmosis, and tuberculosis (and other) pathway genes were evaluated (Figure [10](#F10){ref-type="fig"}). These results revealed that colonization of the rat middle ear with MRSA or PA alone or in combination regulates a significant number of genes. In addition, multi-species colonization with MRSA and PA induced a different set of genes that were not induced by either MRSA or PA alone. This shows that the host response is different after multi-species colonization, which could enhance the pathogenicity of the bacteria.

![**Venn diagram illustrating the number of genes commonly or uniquely differentially expressed in rat middle ear mucosa colonized with methicillin-resistant *Staphylococcus aureus* (MRSA) or *Pseudomonas aeruginosa* (PA) as a single species or multi-species inoculum. (A)** Venn diagram showing significantly (*p* \< 0.05) upregulated genes after colonization with MRSA, PA, or a combination of the two, with respect to the media (control). **(B)** Venn diagram showing significantly (*p* \< 0.05) downregulated genes after MRSA, PA, or multi-species colonization, with respect to media control.](fcimb-07-00125-g0008){#F8}

###### 

**List of genes upregulated ≥1.5-fold (*p* \< 0.05) in rat middle ear mucosae colonized with MRSA and PA and upregulated or downregulated with MRSA or PA single species colonization**.

  **Serial number**   **Gene accession**           **Gene ID**                **Gene name**   **Protein**                                                                     **Fold change in mixed inoculation**   ***p*****-value**   **Fold change with single species SA**   ***p*****-value**   **Fold change with single species PA**   ***p*****-value**
  ------------------- ---------------------------- -------------------------- --------------- ------------------------------------------------------------------------------- -------------------------------------- ------------------- ---------------------------------------- ------------------- ---------------------------------------- -------------------
  1                   [XLOC_007451](XLOC_007451)   [TBIG007451](TBIG007451)   *CHI3L1*        Chitinase-3-like protein 1                                                      1.5                                    0.0127              1.35                                     0.0061              1.21                                     0.0636
  2                   [XLOC_008245](XLOC_008245)   [TBIG008245](TBIG008245)   *PPP2R3D*       Serine/threonine-protein phosphatase 2A regulatory subunit B" subunit delta     1.52                                   0.0412              1.67                                     0.00865             1.38                                     0.08015
  3                   [XLOC_010172](XLOC_010172)   [TBIG010172](TBIG010172)   *JAK3*          Tyrosine-protein kinase JAK3                                                    1.52                                   0.01095             1.31                                     0.01205             1.64                                     0.0179
  4                   [XLOC_016832](XLOC_016832)   [TBIG016832](TBIG016832)   *FCN2*          Ficolin-2                                                                       1.53                                   0.04235             0.547                                    0.38185             0.917                                    0.2557
  5                   [XLOC_015362](XLOC_015362)   [TBIG015362](TBIG015362)   *RT1-BA*        Rano class II histocompatibility antigen, B alpha chain                         1.54                                   0.0146              1.42                                     0.00855             0.573                                    0.35145
  6                   [XLOC_026947](XLOC_026947)   [TBIG026947](TBIG026947)   *TLR7*          Toll-like receptor 7                                                            1.55                                   0.0207              1.68                                     0.0028              1.4                                      0.0428
  7                   [XLOC_023774](XLOC_023774)   [TBIG023774](TBIG023774)   *SLA*           Src-like-adapter                                                                1.55                                   0.01355             1.65                                     0.0038              1.47                                     0.04885
  8                   [XLOC_002817](XLOC_002817)   [TBIG002817](TBIG002817)   *CORO1A*        Coronin-1A                                                                      1.56                                   0.0055              1.5                                      0.00155             1.43                                     0.019
  9                   [XLOC_014051](XLOC_014051)   [TBIG014051](TBIG014051)   *CFI*           Complement factor I                                                             1.57                                   0.04835             0.89                                     0.1797              1.96                                     0.0404
  10                  [XLOC_017708](XLOC_017708)   [TBIG017708](TBIG017708)   *CTSZ*          Cathepsin Z                                                                     1.57                                   0.0143              1.36                                     0.0164              0.876                                    0.19125
  11                  [XLOC_013234](XLOC_013234)   [TBIG013234](TBIG013234)   *CDH6*          Cadherin-6                                                                      1.61                                   0.0029              1.22                                     0.00625             2.64                                     5.00*E*−05
  12                  [XLOC_009200](XLOC_009200)   [TBIG009200](TBIG009200)   *DNASE1L3*      Deoxyribonuclease gamma                                                         1.63                                   0.0323              1.61                                     0.01495             0.767                                    0.3716
  13                  [XLOC_004746](XLOC_004746)   [TBIG004746](TBIG004746)   *PRSS22*        Brain-specific serine protease 4                                                1.66                                   0.0247              0.698                                    0.2435              2.12                                     0.0144
  14                  [XLOC_025304](XLOC_025304)   [TBIG025304](TBIG025304)   *RPLP1*         60S acidic ribosomal protein P1                                                 1.67                                   0.00535             1.6                                      0.00365             0.472                                    0.41575
  15                  [XLOC_024595](XLOC_024595)   [TBIG024595](TBIG024595)   *STRA6*         Stimulated by retinoic acid gene 6 protein homolog                              1.67                                   0.0355              0.526                                    0.4289              2.35                                     0.011
  16                  [XLOC_026676](XLOC_026676)   [TBIG026676](TBIG026676)   *ST8SIA4*       CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase                        1.67                                   0.0333              1.43                                     0.02115             2.04                                     0.01315
  17                  [XLOC_006363](XLOC_006363)   [TBIG006363](TBIG006363)   *TFRC*          Transferrin receptor protein 1                                                  1.69                                   0.0043              0.726                                    0.1144              0.124                                    0.82765
  18                  [XLOC_016540](XLOC_016540)   [TBIG016540](TBIG016540)   *HCK*           Tyrosine-protein kinase HCK                                                     1.7                                    0.00685             1.94                                     0.00045             1.36                                     0.04235
  19                  [XLOC_006164](XLOC_006164)   [TBIG006164](TBIG006164)   *SAMSN1*        SAM domain-containing protein SAMSN-1                                           1.71                                   0.0231              1.8                                      0.00595             1.34                                     0.09725
  20                  [XLOC_019232](XLOC_019232)   [TBIG019232](TBIG019232)   *ENV*           Envelope glycoprotein gp70                                                      1.71                                   0.0325              1.3                                      0.0364              1.87                                     0.0289
  21                  [XLOC_007736](XLOC_007736)   [TBIG007736](TBIG007736)   *LAMB3*         Laminin subunit beta-3                                                          1.71                                   0.0046              1.01                                     0.0415              2.27                                     0.0012
  22                  [XLOC_014992](XLOC_014992)   [TBIG014992](TBIG014992)   *RT1-BB*        Rano class II histocompatibility antigen, B-1 beta chain                        1.72                                   0.0213              1.54                                     0.0081              0.402                                    0.48745
  23                  [XLOC_014993](XLOC_014993)   [TBIG014993](TBIG014993)   *RT1-DB1*       Rano class II histocompatibility antigen, D-1 beta chain                        1.74                                   0.00385             1.59                                     0.00255             1.3                                      0.0427
  24                  [XLOC_020229](XLOC_020229)   [TBIG020229](TBIG020229)   *CNR2*          Cannabinoid receptor 2                                                          1.74                                   0.04435             1.69                                     0.0167              1.57                                     0.12025
  25                  [XLOC_002804](XLOC_002804)   [TBIG002804](TBIG002804)   *LAT*           Linker for activation of T-cells family member 1                                1.77                                   0.0202              1.37                                     0.0229              1.34                                     0.10215
  26                  [XLOC_016951](XLOC_016951)   [TBIG016951](TBIG016951)   *RPS17*         40S ribosomal protein S17                                                       1.8                                    0.04525             1.42                                     0.06125             −0.406                                   0.725
  27                  [XLOC_023263](XLOC_023263)   [TBIG023263](TBIG023263)   *KRT7*          Keratin, type II cytoskeletal 7                                                 1.81                                   0.003               0.839                                    0.10965             2.18                                     0.00285
  28                  [XLOC_025817](XLOC_025817)   [TBIG025817](TBIG025817)   *C3*            Complement C3                                                                   1.85                                   0.0068              1.81                                     0.00065             0                                        1
  29                  [XLOC_015648](XLOC_015648)   [TBIG015648](TBIG015648)   *ELL3*          RNA polymerase II elongation factor ELL3                                        1.9                                    0.04245             1.08                                     0.12345             0.566                                    0.57055
  30                  [XLOC_002984](XLOC_002984)   [TBIG002984](TBIG002984)   *GAL*           Galanin peptides                                                                1.91                                   0.03065             0.656                                    0.36215             −0.583                                   0.604
  31                  [XLOC_016373](XLOC_016373)   [TBIG016373](TBIG016373)   *NMES1*         Normal mucosa of esophagus-specific gene 1 protein                              2.04                                   0.01855             1.79                                     0.0102              1.43                                     0.1201
  32                  [XLOC_018558](XLOC_018558)   [TBIG018558](TBIG018558)   *KLRD1*         Natural killer cells antigen CD94                                               2.07                                   0.0351              1.83                                     0.05635             0.31                                     0.8115
  33                  [XLOC_001187](XLOC_001187)   [TBIG001187](TBIG001187)   *SRCRM_HUMAN*   Putative scavenger receptor cysteine-rich domain-containing protein LOC619207   2.07                                   0.0019              2.57                                     5.00*E*−05          0.401                                    0.5927
  34                  [XLOC_018355](XLOC_018355)   [TBIG018355](TBIG018355)   *CD8A*          T-cell surface glycoprotein CD8 alpha chain                                     2.11                                   0.0217              2.51                                     0.00255             1.2                                      0.23315
  35                  [XLOC_020260](XLOC_020260)   [TBIG020260](TBIG020260)   *PLA2G2D*       Group IID secretory phospholipase A2                                            2.25                                   0.01785             1.44                                     0.0665              0.51                                     0.6369
  36                  [XLOC_023454](XLOC_023454)   [TBIG023454](TBIG023454)   *GZMM*          Granzyme M                                                                      2.41                                   0.0116              2.33                                     0.0055              −0.876                                   0.44375
  37                  [XLOC_005212](XLOC_005212)   [TBIG005212](TBIG005212)   *CCL5*          C-C motif chemokine 5                                                           2.42                                   0.01385             2.05                                     0.00985             −0.559                                   0.6301
  38                  [XLOC_022420](XLOC_022420)   [TBIG022420](TBIG022420)   *HVM17_MOUSE*   Ig heavy chain V region MOPC 47A                                                2.51                                   0.02705             1.16                                     0.22905             0.871                                    0.51305
  39                  [XLOC_015317](XLOC_015317)   [TBIG015317](TBIG015317)   *UBD*           Ubiquitin D                                                                     2.7                                    0.00275             1.93                                     0.00665             1.14                                     0.2022
  40                  [XLOC_011426](XLOC_011426)   [TBIG011426](TBIG011426)   *TCC2_MOUSE*    T-cell receptor gamma chain C region C7.5                                       2.72                                   0.0168              3.31                                     0.00035             0.352                                    0.78555
  41                  [XLOC_006104](XLOC_006104)   [TBIG006104](TBIG006104)   *LV2B_MOUSE*    Ig lambda-2 chain V region MOPC 315                                             2.8                                    0.002               0.785                                    0.2881              0.937                                    0.33275
  42                  [XLOC_018648](XLOC_018648)   [TBIG018648](TBIG018648)   *KLRB1F*        Killer cell lectin-like receptor subfamily B member 1F                          2.82                                   0.02                2.45                                     0.02085             0.0885                                   0.9476
  43                  [XLOC_012586](XLOC_012586)   [TBIG012586](TBIG012586)   *CLEC3A*        C-type lectin domain family 3 member A                                          3.07                                   0.04855             3.67                                     0.014               1.08                                     0.46495
  44                  [XLOC_022400](XLOC_022400)   [TBIG022400](TBIG022400)   *HVM43_MOUSE*   Ig heavy chain V region MOPC 141                                                3.15                                   0.04835             3.26                                     0.06595             0.34                                     0.8163

###### 

**List of genes downregulated by ≥1.5-fold (*p* \< 0.05) in rat middle ear mucosae colonized by MRSA and PA and either downregulated or upregulated with MRSA or PA single species colonization**.

  **Serial number**   **Gene accession**           **Gene ID**                **Gene name**     **Protein**                                                                                         **Fold change in mixed inoculation**   ***p*****-value**   **Fold change with single species SA**   ***p*****-value**   **Fold change with single species PA**   ***p*****-value**
  ------------------- ---------------------------- -------------------------- ----------------- --------------------------------------------------------------------------------------------------- -------------------------------------- ------------------- ---------------------------------------- ------------------- ---------------------------------------- -------------------
  1                   [XLOC_000033](XLOC_000033)   [TBIG000033](TBIG000033)   *TXLNB*           Beta-taxilin                                                                                        −7.41                                  0.04245             −1.39                                    0.01125             −7.68                                    0.07995
  2                   [XLOC_005477](XLOC_005477)   [TBIG005477](TBIG005477)   *SCN4A*           Sodium channel protein type 4 subunit alpha                                                         −5.49                                  0.02615             −1.34                                    0.074               −4.26                                    0.11755
  3                   [XLOC_021210](XLOC_021210)   [TBIG021210](TBIG021210)   *GAG*             Gag polyprotein                                                                                     −5.22                                  0.044               0.78                                     0.2248              −0.722                                   0.4373
  4                   [XLOC_027720](XLOC_027720)   [TBIG027720](TBIG027720)   *IGSF1*           Immunoglobulin superfamily member 1                                                                 −4.53                                  0.0182              −1.13                                    0.19385             −5.06                                    0.14935
  5                   [XLOC_013130](XLOC_013130)   [TBIG013130](TBIG013130)   *LDLRAD1*         Low-density lipoprotein receptor class A domain-containing protein 1                                −4.36                                  0.0083              −1.15                                    0.2058              −1.93                                    0.15705
  6                   [XLOC_027382](XLOC_027382)   [TBIG027382](TBIG027382)   *POL*             Retrovirus-related Pol polyprotein LINE-1                                                           −4.29                                  0.0183              −1.76                                    0.07165             −4.89                                    0.095
  7                   [XLOC_012347](XLOC_012347)   [TBIG012347](TBIG012347)   *GAG-POL*         Gag-Pol polyprotein                                                                                 −4.25                                  0.00015             0.841                                    0.0705              −0.867                                   0.15245
  8                   [XLOC_015004](XLOC_015004)   [TBIG015004](TBIG015004)   *TNXB*            Tenascin-X                                                                                          −4.14                                  0.0376              −2.21                                    0.25835             −3                                       0.0938
  9                   [XLOC_024947](XLOC_024947)   [TBIG024947](TBIG024947)   *GRIA4*           Glutamate receptor 4                                                                                −4.06                                  0.04955             −1.7                                     0.0813              −2.26                                    0.1075
  10                  [XLOC_014321](XLOC_014321)   [TBIG014321](TBIG014321)   *TTC24*           Tetratricopeptide repeat protein 24                                                                 −4.04                                  0.0285              −0.657                                   0.4197              −1.2                                     0.28155
  11                  [XLOC_026757](XLOC_026757)   [TBIG026757](TBIG026757)   *POL*             Pol polyprotein                                                                                     −4.03                                  0.02135             0.779                                    0.21675             1.18                                     0.15825
  12                  [XLOC_020111](XLOC_020111)   [TBIG020111](TBIG020111)   *NT5C1A*          Cytosolic 5\'-nucleotidase 1A                                                                       −3.93                                  0.00125             −1.39                                    0.0508              −2.43                                    0.0548
  13                  [XLOC_002039](XLOC_002039)   [TBIG002039](TBIG002039)   *MARK4*           MAP/microtubule affinity-regulating kinase 4                                                        −3.65                                  0.0475              −1.43                                    0.4849              −3.48                                    0.0536
  14                  [XLOC_007497](XLOC_007497)   [TBIG007497](TBIG007497)   *BRINP3*          BMP/retinoic acid-inducible neural-specific protein 3                                               −3.63                                  0.0429              −1.46                                    0.1324              −3.66                                    0.13615
  15                  [XLOC_024201](XLOC_024201)   [TBIG024201](TBIG024201)   *POL*             Pol polyprotein                                                                                     −3.57                                  0.0373              −0.937                                   0.2889              −1.6                                     0.2579
  16                  [XLOC_006129](XLOC_006129)   [TBIG006129](TBIG006129)   *POL*             Pol polyprotein                                                                                     −3.38                                  0.04745             −1.18                                    0.207               −1.52                                    0.34225
  17                  [XLOC_005475](XLOC_005475)   [TBIG005475](TBIG005475)   *GH1*             Somatotropin                                                                                        −3.34                                  0.04165             0.851                                    0.2985              −0.925                                   0.49845
  18                  [XLOC_024602](XLOC_024602)   [TBIG024602](TBIG024602)   *HCN4*            Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4                      −3.27                                  0.03825             −0.742                                   0.37845             −1.53                                    0.27585
  19                  [XLOC_021698](XLOC_021698)   [TBIG021698](TBIG021698)   *RGS6*            Regulator of G-protein signaling 6                                                                  −3.25                                  0.02615             −1.38                                    0.14185             −1.96                                    0.20475
  20                  [XLOC_006065](XLOC_006065)   [TBIG006065](TBIG006065)   *OSTN*            Osteocrin                                                                                           −3.23                                  0.04325             −1.79                                    0.04165             −2.8                                     0.081
  21                  [XLOC_021434](XLOC_021434)   [TBIG021434](TBIG021434)   *ALK*             ALK tyrosine kinase receptor                                                                        −3.18                                  0.0397              −1.86                                    0.0675              −3.07                                    0.08475
  22                  [XLOC_026950](XLOC_026950)   [TBIG026950](TBIG026950)   *EGFL6*           Epidermal growth factor-like protein 6                                                              −3.13                                  0.0404              −0.986                                   0.2498              −1.45                                    0.2599
  23                  [XLOC_021001](XLOC_021001)   [TBIG021001](TBIG021001)   *NCMAP*           Noncompact myelin-associated protein                                                                −3.13                                  0.0497              −1.11                                    0.50945             −1.23                                    0.5089
  24                  [XLOC_004000](XLOC_004000)   [TBIG004000](TBIG004000)   *GRIA1*           Glutamate receptor 1                                                                                −3.05                                  0.0488              −2.95                                    0.0636              −2.59                                    0.0773
  25                  [XLOC_021987](XLOC_021987)   [TBIG021987](TBIG021987)   *KCNK3*           Potassium channel subfamily K member 3                                                              −2.98                                  0.03695             −2.13                                    0.0539              −2.07                                    0.1183
  26                  [XLOC_008308](XLOC_008308)   [TBIG008308](TBIG008308)   *NAA11*           N-alpha-acetyltransferase 11                                                                        −2.97                                  0.02785             −1.27                                    0.1347              −1.53                                    0.1725
  27                  [XLOC_003922](XLOC_003922)   [TBIG003922](TBIG003922)   *TRIM7*           Tripartite motif-containing protein 7                                                               −2.93                                  0.0133              −1.02                                    0.11075             −1.47                                    0.10675
  28                  [XLOC_010040](XLOC_010040)   [TBIG010040](TBIG010040)   *POL*             Pol polyprotein                                                                                     −2.86                                  0.01455             −1.46                                    0.06215             −2.43                                    0.0726
  29                  [XLOC_017690](XLOC_017690)   [TBIG017690](TBIG017690)   *BCAS1*           Breast carcinoma-amplified sequence 1 homolog                                                       −2.65                                  0.04765             −1.54                                    0.07675             −0.974                                   0.3948
  30                  [XLOC_002797](XLOC_002797)   [TBIG002797](TBIG002797)   *SNRPN*           Small nuclear ribonucleoprotein-associated protein N                                                −2.65                                  0.0201              −1.4                                     0.06855             −2.02                                    0.06625
  31                  [XLOC_023030](XLOC_023030)   [TBIG023030](TBIG023030)   *COL14A1*         Collagen alpha-1(XIV) chain                                                                         −2.62                                  0.0069              −0.904                                   0.16355             −1.16                                    0.15975
  32                  [XLOC_023753](XLOC_023753)   [TBIG023753](TBIG023753)   *KLHL38*          Kelch-like protein 38                                                                               −2.62                                  0.0302              −0.989                                   0.17215             −2.69                                    0.0851
  33                  [XLOC_002608](XLOC_002608)   [TBIG002608](TBIG002608)   *HBB2_RAT*        Hemoglobin subunit beta-2                                                                           −2.55                                  0.0001              −2.36                                    5.00*E*−05          −3.34                                    5.00*E*−05
  34                  [XLOC_024012](XLOC_024012)   [TBIG024012](TBIG024012)   *COL2A1*          Collagen alpha-1(II) chain                                                                          −2.51                                  0.00715             −0.616                                   0.24645             1.09                                     0.10775
  35                  [XLOC_007817](XLOC_007817)   [TBIG007817](TBIG007817)   *NFASC*           Neurofascin                                                                                         −2.46                                  0.02025             −1.47                                    0.09665             −2.29                                    0.08025
  37                  [XLOC_018133](XLOC_018133)   [TBIG018133](TBIG018133)   *MEST*            Mesoderm-specific transcript homolog protein                                                        −2.43                                  0.03235             −1.11                                    0.1112              −1.91                                    0.07395
  38                  [XLOC_022758](XLOC_022758)   [TBIG022758](TBIG022758)   *LINGO3*          Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 3   −2.35                                  0.0387              −1.42                                    0.0885              −1.4                                     0.18525
  39                  [XLOC_005055](XLOC_005055)   [TBIG005055](TBIG005055)   *CHRNB1*          Acetylcholine receptor subunit beta                                                                 −2.25                                  0.0174              −1.12                                    0.10445             −1.7                                     0.08505
  40                  [XLOC_009184](XLOC_009184)   [TBIG009184](TBIG009184)   *CDHR3*           Cadherin-related family member 3                                                                    −2.25                                  0.04445             −0.978                                   0.13985             −1.47                                    0.15415
  41                  [XLOC_014711](XLOC_014711)   [TBIG014711](TBIG014711)   *CAPSL*           Calcyphosin-like protein                                                                            −2.24                                  0.04895             −0.886                                   0.25825             −0.976                                   0.37135
  42                  [XLOC_003432](XLOC_003432)   [TBIG003432](TBIG003432)   *POL*             Pol polyprotein                                                                                     −2.11                                  0.0243              −1.35                                    0.0438              −1.65                                    0.07025
  43                  [XLOC_022093](XLOC_022093)   [TBIG022093](TBIG022093)   *EGLN3*           Egl nine homolog 3                                                                                  −2.09                                  0.02785             −0.962                                   0.11                −0.67                                    0.37785
  44                  [XLOC_017633](XLOC_017633)   [TBIG017633](TBIG017633)   *MATN4*           Matrilin-4 \[Source:SWISS;Acc:O89029\]                                                              −2.02                                  0.0068              −0.87                                    0.0838              −0.925                                   0.15585
  45                  [XLOC_017934](XLOC_017934)   [TBIG017934](TBIG017934)   *GAG-POL*         Gag-Pol polyprotein                                                                                 −1.92                                  0.0217              −0.381                                   0.4882              −0.885                                   0.2449
  46                  [XLOC_000295](XLOC_000295)   [TBIG000295](TBIG000295)   *SSC5D*           Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D                            −1.91                                  0.00235             −0.86                                    0.062               −1.13                                    0.05595
  47                  [XLOC_020236](XLOC_020236)   [TBIG020236](TBIG020236)   *TCEA3*           Transcription elongation factor A protein 3                                                         −1.8                                   0.04715             −0.75                                    0.2413              −1.45                                    0.1176
  48                  [XLOC_019566](XLOC_019566)   [TBIG019566](TBIG019566)   *POL*             Pol polyprotein                                                                                     −1.75                                  0.00645             −0.592                                   0.29525             −1.36                                    0.0589
  49                  [XLOC_024924](XLOC_024924)   [TBIG024924](TBIG024924)   *FAM198A*         Protein FAM198A                                                                                     −1.68                                  0.04485             −0.975                                   0.104               −1.57                                    0.0906
  50                  [XLOC_016802](XLOC_016802)   [TBIG016802](TBIG016802)   \-                \-                                                                                                  −1.68                                  0.01715             −0.262                                   0.6802              −1.08                                    0.13725
  51                  [XLOC_010859](XLOC_010859)   [TBIG010859](TBIG010859)   *AGTPBP1*         Cytosolic carboxypeptidase 1                                                                        −1.67                                  0.01575             −0.817                                   0.1006              −1.66                                    0.0367
  52                  [XLOC_002382](XLOC_002382)   [TBIG002382](TBIG002382)   *ST8SIA2*         Alpha-2,8-sialyltransferase 8B                                                                      −1.67                                  0.04965             −0.846                                   0.171               −1.09                                    0.23515
  53                  [XLOC_026579](XLOC_026579)   [TBIG026579](TBIG026579)   *CCDC108*         Coiled-coil domain-containing protein 108                                                           −1.66                                  0.01635             −0.31                                    0.5204              −0.735                                   0.2972
  54                  [XLOC_027640](XLOC_027640)   [TBIG027640](TBIG027640)   *CHRDL1*          Chordin-like protein 1                                                                              −1.62                                  0.00485             −0.842                                   0.0639              −1.81                                    0.0037
  55                  [XLOC_002898](XLOC_002898)   [TBIG002898](TBIG002898)   *ADAM8*           Disintegrin and metalloproteinase domain-containing protein 8                                       −1.59                                  0.00935             −0.908                                   0.0545              −0.97                                    0.12135
  56                  [XLOC_021028](XLOC_021028)   [TBIG021028](TBIG021028)   *UBXN10*          UBX domain-containing protein 10                                                                    −1.58                                  0.01805             −0.353                                   0.5061              −1.22                                    0.08675
  57                  [XLOC_013884](XLOC_013884)   [TBIG013884](TBIG013884)   *C1ORF173*        Uncharacterized protein C1orf173                                                                    −1.56                                  0.019               −0.068                                   0.88615             −0.855                                   0.18325
  58                  [XLOC_024898](XLOC_024898)   [TBIG024898](TBIG024898)   *DLEC1*           Deleted in lung and esophageal cancer protein 1                                                     −1.56                                  0.03495             −0.467                                   0.3517              −1.07                                    0.14125
  59                  [XLOC_001829](XLOC_001829)   [TBIG001829](TBIG001829)   *SLC22A3*         Solute carrier family 22 member 3                                                                   inf                                    5.00*E*−05          −1.36                                    0.2606              −3.68                                    0.19145
  60                  [XLOC_003476](XLOC_003476)   [TBIG003476](TBIG003476)   *POL*             Pol polyprotein                                                                                     inf                                    5.00*E*05           −0.582                                   0.23855             −10.4                                    0.2431
  61                  [XLOC_004811](XLOC_004811)   [TBIG004811](TBIG004811)   *RPS2*            40S ribosomal protein S2                                                                            inf                                    5.00*E*−05          0.17                                     0.71865             inf                                      5.00*E*−05
  62                  [XLOC_006114](XLOC_006114)   [TBIG006114](TBIG006114)   *RPL9*            60S ribosomal protein L9                                                                            inf                                    5.00*E*−05          −0.538                                   0.5414              inf                                      5.00*E*−05
  63                  [XLOC_006289](XLOC_006289)   [TBIG006289](TBIG006289)   *MYH15*           Myosin-15                                                                                           inf                                    5.00*E*−05          −1.09                                    0.28855             −6.22                                    0.2431
  64                  [XLOC_006508](XLOC_006508)   [TBIG006508](TBIG006508)   *GAG*             Gag polyprotein                                                                                     inf                                    5.00*E*−05          −0.187                                   0.8494              −3.29                                    0.21805
  65                  [XLOC_009108](XLOC_009108)   [TBIG009108](TBIG009108)   *GAG-POL*         Gag-Pol polyprotein                                                                                 inf                                    5.00*E*−05          −0.5                                     0.5663              −6.64                                    0.24325
  66                  [XLOC_013224](XLOC_013224)   [TBIG013224](TBIG013224)   *RPS2*            40S ribosomal protein S2                                                                            inf                                    5.00*E*−05          0.11                                     0.8856              −7.12                                    0.24315
  67                  [XLOC_017320](XLOC_017320)   [TBIG017320](TBIG017320)   *ACTC1*           Actin, alpha cardiac muscle 1                                                                       inf                                    5.00*E*−05          −0.929                                   0.0515              −11.1                                    0.2431
  68                  [XLOC_022977](XLOC_022977)   [TBIG022977](TBIG022977)   *STAC3*           SH3 and cysteine-rich domain-containing protein 3                                                   inf                                    5.00*E*−05          −1.31                                    0.0224              −8.87                                    0.1708
  69                  [XLOC_023915](XLOC_023915)   [TBIG023915](TBIG023915)   *CYP2D1*          Cytochrome P450 2D1                                                                                 inf                                    5.00*E*−05          1.29                                     0.09275             −4.64                                    0.16405
  70                  [XLOC_026493](XLOC_026493)   [TBIG026493](TBIG026493)   *MSTN*            Growth/differentiation factor 8                                                                     inf                                    5.00*E*−05          −2.2                                     0.1506              −5.46                                    0.2456
  71                  [XLOC_027253](XLOC_027253)   [TBIG027253](TBIG027253)   *CX064_MOUSE*     Uncharacterized protein CXorf64 homolog                                                             inf                                    5.00*E*−05          −1.48                                    0.1895              −5.75                                    0.2454
  72                  [XLOC_022618](XLOC_022618)   [TBIG022618](TBIG022618)   *ENV*             Envelope glycoprotein                                                                               inf                                    0.0004              −0.993                                   0.41135             inf                                      0.0008
  73                  [XLOC_005431](XLOC_005431)   [TBIG005431](TBIG005431)   *NEDD4*           E3 ubiquitin-protein ligase NEDD4                                                                   inf                                    0.00345             −1.81                                    0.2551              −4.4                                     0.25485
  74                  [XLOC_016973](XLOC_016973)   [TBIG016973](TBIG016973)   *NEB*             Nebulin                                                                                             inf                                    0.00495             −0.73                                    0.57485             −2.83                                    0.2479
  75                  [XLOC_019744](XLOC_019744)   [TBIG019744](TBIG019744)   *CALB1*           Calbindin                                                                                           inf                                    0.0053              −1.73                                    0.2773              −3.48                                    0.2558
  76                  [XLOC_020636](XLOC_020636)   [TBIG020636](TBIG020636)   *15.5 KDA FABP*   Major urinary protein                                                                               inf                                    0.0053              −3.54                                    0.1979              −2.95                                    0.2434
  77                  [XLOC_022462](XLOC_022462)   [TBIG022462](TBIG022462)   *HV208_HUMAN*     Ig heavy chain V-II region SESS                                                                     inf                                    0.0053              −0.717                                   0.578               −4.71                                    0.2508
  78                  [XLOC_027795](XLOC_027795)   [TBIG027795](TBIG027795)   *POL*             Pol polyprotein                                                                                     inf                                    0.0053              −3                                       0.1555              −3.64                                    0.25175
  79                  [XLOC_007006](XLOC_007006)   [TBIG007006](TBIG007006)   *KIF19*           Kinesin-like protein KIF19                                                                          inf                                    0.0058              −1.9                                     0.2472              −4.39                                    0.2531
  80                  [XLOC_017904](XLOC_017904)   [TBIG017904](TBIG017904)   *POL*             Retrovirus-related Pol polyprotein LINE-1                                                           inf                                    0.00575             −3.28                                    0.2009              −1.76                                    0.3774
  81                  [XLOC_019217](XLOC_019217)   [TBIG019217](TBIG019217)   *OXTR*            Oxytocin receptor                                                                                   inf                                    0.0058              −2.29                                    0.19495             −4.46                                    0.2524
  82                  [XLOC_007150](XLOC_007150)   [TBIG007150](TBIG007150)   *DNAH10*          Dynein heavy chain 10, axonemal                                                                     inf                                    0.01035             −3.34                                    0.26695             −2.62                                    0.2963
  83                  [XLOC_016972](XLOC_016972)   [TBIG016972](TBIG016972)   *NEB*             Nebulin                                                                                             inf                                    0.0097              −2.55                                    0.23375             −3.61                                    0.2679
  84                  [XLOC_009140](XLOC_009140)   [TBIG009140](TBIG009140)   *DUSP13*          Dual specificity protein phosphatase 13 isoform A                                                   inf                                    0.0117              −0.865                                   0.6321              −3.34                                    0.27455
  85                  [XLOC_006921](XLOC_006921)   [TBIG006921](TBIG006921)   *CD209L2*         CD209 antigen-like protein 2                                                                        inf                                    0.01335             −0.951                                   0.6269              −3.07                                    0.2863
  86                  [XLOC_009994](XLOC_009994)   [TBIG009994](TBIG009994)   *GAG*             Gag polyprotein                                                                                     inf                                    0.01335             1.01                                     0.46895             0.352                                    0.8164
  87                  [XLOC_009143](XLOC_009143)   [TBIG009143](TBIG009143)   *DUSP13*          Dual specificity protein phosphatase 13 isoform A                                                   inf                                    0.0252              −0.929                                   0.6643              −2.67                                    0.42285
  88                  [XLOC_007324](XLOC_007324)   [TBIG007324](TBIG007324)   *POL*             Pol polyprotein                                                                                     inf                                    0.0387              0.404                                    0.83325             0.731                                    0.77005

![**Gene ontology (GO) of differentially expressed genes in rat middle ear mucosa colonized with methicillin-resistant *Staphylococcus aureus* (MRSA) or *Pseudomonas aeruginosa* (PA) as a single or multi-species inoculum. (A)** GO category of significantly (*p* \< 0.05) upregulated genes (by ≥1.5-fold) with multi-species colonization. **(B)** GO category of significantly (*p* \< 0.05) downregulated genes (≥1.5-fold) after multi-species colonization.](fcimb-07-00125-g0009){#F9}

![**KEGG pathway analysis using string showing significantly (*p* \< 0.05) upregulated genes (by ≥1.5-fold) after multi-species colonization of the rat middle ear mucosa**.](fcimb-07-00125-g0010){#F10}

Quantification of gene expression using real-time RT-PCR
--------------------------------------------------------

The results of real time-PCR were in complete agreement with RNA sequencing gene expression results. The expression of *RPS9, MMP12, ITGB2, CST7, SCTR, APOC1, CD69*, and *CCNO* genes was significantly (*p* \< 0.05) upregulated (by \>1.5-fold) in rat mucosae colonized with MRSA or PA alone or in combination based on both real time RT-PCR and RNA sequencing (Table [4](#T4){ref-type="table"}). Similarly, the expression of *KERA, GPD1, ACTA1, EEF1A2, HRC, FOXD1, MYH1, SYNPO2L, TNMD*, and *MYOM2*, based on real time RT-PCR and RNA sequencing, was significantly (*p* \< 0.05) decreased by more than 1.5-fold (Table [4](#T4){ref-type="table"}).

###### 

**Confirmation of RNA sequencing results by real-time RT-PCR**.

       **Gene name**   **Rat colonized with multi-species culture**   **Rat colonized with MRSA single species**   **Rat colonized with PA single species**                    
  ---- --------------- ---------------------------------------------- -------------------------------------------- ------------------------------------------ -------- ------- -------
  1    *RPS9*          4.27                                           3.23                                         3.72                                       1.87     3.97    2.71
  2    *MMP12*         2.67                                           1.34                                         4.2                                        1.11     2.51    2.0
  3    *ITGB2*         2.02                                           25.28                                        2.42                                       12.55    2.15    7.36
  4    *CST7*          3.09                                           7.2                                          3.12                                       13.45    2.09    1.7
  5    *SCTR*          4.26                                           15.78                                        5.18                                       20.11    4.13    18.25
  6    *APOC1*         3.4                                            11.55                                        3.95                                       4.99     2.88    2.9
  7    *CD69*          3.36                                           12.04                                        3.44                                       14.32    2.71    1.7
  8    *CCNO*          2.8                                            5.6                                          3.68                                       11.31    3.74    3.78
  9    *KERA*          −9.37                                          −5.55                                        −2.19                                      −7.69    −5.66   −6.6
  10   *GPD1*          −6.4                                           −6.66                                        −1.62                                      −8.33    −6.1    −5.82
  11   *EEF1A2*        −7.31                                          −3.3                                         −1.36                                      −4.76    −6.93   −1.5
  12   *HRC*           −6.77                                          −4                                           −1.62                                      −6.2     −6.73   −5.8
  13   *FOXD1*         −4.94                                          −4.34                                        −2.16                                      −8.33    −4.37   −6.25
  14   *MYH1*          −10.9                                          −3.33                                        −2.36                                      −4.76    −10.5   −4
  15   *SYNPO21*       −5.98                                          −5.26                                        −1.42                                      −7.1     −5.59   −3.84
  16   *TNMD*          −7.12                                          −9                                           −1.88                                      −8.3     −7.3    −7.69
  17   *MYOM2*         −7.1                                           −7.6                                         −2.61                                      −5.2     −6.65   −4
  18   *ACTA1*         −11.5                                          −5.55                                        −1.36                                      −16.66   −10.1   −2.70

Discussion {#s4}
==========

*S. aureus* and PA are known to cause biofilm-related infections and are frequently found together in chronically infected wounds, CF, CSOM, and on indwelling medical devices such as prostheses, stents, implants, catheters, and endotracheal tubes (Chole and Faddis, [@B7]; Hubert et al., [@B27]; Percival et al., [@B50]). Previous studies using a wound infection model suggested that poly-microbial infections of MRSA and PA were more virulent than single species infections and that synergism exists between these species, which increases virulence (Hendricks et al., [@B24]; Pastar et al., [@B48]). In various types of chronic ear infections, MRSA and PA have been frequently isolated, and these bacteria co-exist; however, their interaction with each-other or with the host was previously unknown (Klein and Chan, [@B32]; Kim et al., [@B31]). In this study, we investigated MRSA and PA multi-species biofilm communities *in vitro* and their interaction with the host during *in vivo* colonization using an OM rat model.

CV microtiter plate assay results showed significantly increased biofilm biomass in multi-species biofilms of MRSA and PA in comparison with that of single species biofilms of either MRSA or PA. It was speculated that the matrix produced by the two bacterial species and cellular components of the bacteria contributes to increased biomass. It is suggested that Staphylococcus and Pseudomonas biofilm matrix consist of extracellular DNA (e-DNA) along with exopolysaccharides (Whitchurch et al., [@B62]; Eckhart et al., [@B15]). Staphylococcal biofilm accumulation is mediated by polysaccharide intercellular adhesion (PIA), modulated by gene products encoded by *ica* operon (Cramton et al., [@B10]), and can also form *ica*-independent biofilm, mediated by proteins binding of the extracellular matrix (Vergara-Irigaray et al., [@B60]). MRSA isolates are known to produce *ica*-independent biofilms (Fitzpatrick et al., [@B18]). While the PA biofilms matrix consists of alginate (a negatively charged polymer of guluronic and mannuronic acid), Psl (a neutral polysaccharide consisting of a pentasaccharide repeat containing glucose, mannose, and rhamnose), and Pel (positively charged exopolysaccharide composed of partially acetylated 1 → 4 glycosidic linkages of *N*-acetylgalactosamine and *N*-acetylglucosamine) (Franklin et al., [@B20]). However, MRSA CFU counts were significantly lower (by \>2-fold) than those of PA. These results are in agreement with previous studies that demonstrated that *S. aureus* and PA are frequently found together in human infections, and that PA kills *S. aureus* when the two species are grown together in nutrient rich medium *in vitro* (Palmer et al., [@B47], [@B46]; Voggu et al., [@B61]). The killing of *S. aureus* has been attributed to various exoproducts of PA such as LasA protease (Mansito et al., [@B39]), HQNO (Hoffman et al., [@B26]), *pel* and *psl* products (Qin et al., [@B52]), and pyocyanin (Dietrich et al., [@B12]). SEM images also confirmed the presence of few MRSA bacteria in multi-species biofilms; however, increased EPS matrix was visible in multi-species biofilms, compared to that in single species biofilms. Many studies have suggested that *S. aureus* can overcome this suppression and escape PA-mediated cell death by growing as SCVs, which are characterized as a respiration-defective subpopulation with an altered phenotype (Biswas et al., [@B3]; Nair et al., [@B44]). Moreover, *S. aureus* forms SCVs in the presence of HQNO produced by PA (Hoffman et al., [@B26]). In addition, these SCVs that were shown to form under stress of HQNO formed robust *in vitro* biofilms through the activation of SigB and the repression of agr (Mitchell et al., [@B43]). Our results also showed robust biofilm formation by MRSA 3903 in the presence of HQNO, when compared to that in the control. SEM results provided further evidence of significant biofilm formation in the presence of HQNO. This process has been suggested to be due to the activation of SigB and the repression of agr, which upregulates various cell surface proteins such as FnBA, which are involved in biofilm formation (Mitchell et al., [@B42], [@B41], [@B43]).

*S. aureus* and PA frequently colonize the upper respiratory tract and cause several chronic diseases including chronic OM, cholesteatoma, chronic adenoiditis, chronic sinusitis, post-operative trampansomay, and nasal polyposis (Bendouah et al., [@B2]; Boase et al., [@B4]). Furthermore, MRSA and PA have been frequently isolated from chronic ear infections such as CSOM (Jung et al., [@B28]; Kim et al., [@B31]). In this study, we used the OM rat model to study the interaction between MRSA and PA *in vivo*. We previously used this model to study the colonization of *S. aureus* and *Streptococcus pneumoniae* separately in the rat middle ear (Yadav et al., [@B65], [@B67], [@B64]). Herein, we first evaluated the utility of the OM rat model for multi-species colonization. The results showed consistent recovery of MRSA or PA from the rat middle ear, which was associated with significant inflammation. We choose the OM rat model over other animal models because the rat middle ear is a natural habitat for *S. aureus* and PA, and because inflammation in the middle ear mucosa (due to bacterial challenge or infection) results in severe swelling that can be easily visualized by SEM; this tissue can also be easily recovered for gene expression studies.

The middle ear is a natural habitat for many bacteria including normal body flora or opportunistic pathogens. Both *S. aureus* and PA have been isolated from middle ear infections (Brook, [@B5]). Our *in vivo* results showed marked recovery of MRSA or PA after multi-species and single species inoculation with significant inflammation in the rat middle ear. In addition, no significant differences in CFU counts between MRSA and PA were observed after multi-species inoculation. These results indicate that MRSA and PA successfully colonized the rat middle ear with no significant inhibition of either species. Using wound infection and rabbit models, DeLeon et al. (2014) reported no inhibition of *S. aureus* in the presence of PA during multi-species *in vivo* colonization (DeLeon et al., [@B11]). Other studies also showed a lack of inhibition in the absence of nutrient rich medium, which could be due to the presence of SCVs of *S. aureus* (McNamara and Proctor, [@B40]; Filkins et al., [@B17]). Inflammation in the middle ear is a sign of infection; our results also detected significant inflammation in this tissue after inoculation with either MRSA or PA alone or in combination. The significant number of bacteria recovered (based on CFU counts) indicates that multi-species bacterial colonization was established in the middle ear. SEM analysis also confirmed the presence of biofilm-like structures that were deposited on the cilia of the middle ear after single or multi-species inoculation. However, those of MRSA or PA alone were indistinguishable. Similarly, Kaya et al. ([@B30]) also detected poly-microbial biofilms of *S. aureus* and PA in the middle ear (Saunders et al., [@B53]; Kaya et al., [@B30]). In CRS patients, multi-species biofilms have been associated with increased mucosal inflammation, more severe osteitis, higher incidence of recurrent infection (Li et al., [@B33]; Dong et al., [@B14]) and postoperative outcome (Singhal et al., [@B56]), and post-surgery progressions (Bendouah et al., [@B2]).

To analyze differential gene expression in rat middle ear mucosae inoculated with MRSA or PA alone or in combination, RNA sequencing of the total transcriptome was performed. RNA-seq results detected significantly increased expression of defense-, immune-, response-, and inflammatory-related genes after multi-species colonization and decreased expression of signaling, development, and communication pathway genes. Interestingly, a total of 122 genes (62 upregulated and 160 downregulated) were exclusively differentially regulated by multi-species colonization, and these genes were not expressed with either MRSA or PA inoculation. Gene pathway analysis revealed that those genes are involved in the phagosome, antigen processing and presentation, influenza A infection, *Staphylococcus* infection, herpes virus infection, toxoplasmosis, and tuberculosis among others.

*FCN2, CFI, KLRD1, KLRB1F, UBD, CCL5*, and *GAL* were significantly upregulated after multi-species inoculation and were either downregulated or insignificantly upregulated with MRSA or PA single inoculation. The ficolin-2-encoding gene *FCN2*, was upregulated by 1.52-fold (*P* = 0.04) with multi-species infection and was downregulated after inoculation with MRSA or PA alone. Ficolin activates the lectin pathway of complement by specifically binding to lipoteichoic acid, a cell wall constituent of gram-positive bacteria, and initiates an innate anti-microbial immune response (Lynch et al., [@B38]). The *CFI* gene was significantly upregulated in multi-species infections and was downregulated with MRSA or PA alone. *CFI* encodes complement factor I, which is involved in complement activation during cochlear responses to acoustic trauma (Patel et al., [@B49]). The *KLRD1* and *KLRB1F* genes encode the killer cell lectin-like receptor subfamily K, member 1 protein and killer cell lectin like receptor B1, which are involved in the activation of immune responses and cytotoxicity, were upregulated by 2.1- and 2.0-fold, respectively, after mixed culture inoculation, and were downregulated with MRSA or PA alone (Taniguchi et al., [@B58]). The *UBD* gene, encoding the protein ubiquitin D, which is involved in cytokine-induced apoptosis in rat, was upregulated by mixed cultures and MRSA and was downregulated with PA alone (Brozzi et al., [@B6]). Similarly, the *CCL5* gene encodes chemokine (C-C Motif) ligand 5 protein. These chemokine proteins are involved in immunoregulatory and inflammatory processes. CCL5 is an essential factor for the induction and maintenance of protective pneumococcal immunity (Palaniappan et al., [@B45]). The *GAL* gene encodes galanin peptides, and was upregulated by 1.9-fold or repressed with SA or PA, respectively. The galanin protein is involved in post-traumatic stress disorder and mild blast-induced traumatic brain injury (Kawa et al., [@B29]). The upregulation of important immune response- and cytotoxicity-related genes after multispecies inoculation indicates an enhanced host response, when compared to that after inoculation with MRSA and PA alone.

*DLECI, ST8SIA2*, and *SSC5d* are important genes, which were downregulated with multi-species inoculation and either upregulated or insignificantly downregulated with MRSA or PA alone. The *DLEC1* gene encodes the deleted in lung and esophageal cancer 1 protein (DLECI) that has tumor suppressive activities. The downregulation of this gene has been observed in several human cancers including lung, esophageal, renal, and head and neck squamous cell carcinoma (Zhang et al., [@B68]). Similarly, the *ST8SIA2* gene encodes alpha-2,8-sialyltransferase 2, which is involved in neuronal plasticity (Shaw et al., [@B55]). The *SSC5D* gene encodes scavenger receptor cysteine rich family member with 5 domains protein, which induces bacterial and fungal aggregation and subsequent inhibition of PAMP-induced cytokine release, and was also downregulated after multi-species inoculation. These results indicate that multi-species colonization triggers host responses that are different from those induced by infection with MRSA or PA alone. It has been previously reported that poly-microbial biofilms of *S. aureus* and PA, in a chronic wound infection model, significantly impair wound healing relative to that observed with their single-species biofilm counterparts. Multi-species biofilms also trigger enhanced host inflammatory responses through the expression of *IL-1*β and *TNF-*α (Seth et al., [@B54]). Similarly, Pastar et al. ([@B48]) also detected significantly decreased re-epithelization with mixed species biofilms, via the suppression of keratinocyte growth factor-1. Moreover, in poly-microbial wound infections, the presence of PA induced the expression of *S. aureus* virulence factors including Panton-Valentine leucocidin and α-hemolysin (Pastar et al., [@B48]).

Conclusion {#s5}
==========

This study demonstrated that MRSA and PA could co-exist in poly-microbial biofilms *in vitro*, and colonize the rat middle ear *in vivo*. The poly-microbial colonization of MRSA and PA induced the differential expression of a significant number of genes that are involved in immune response, inflammation, signaling, development, and defense; these were not expressed with single species colonization by either MSA or PA. These results indicate that poly-microbial colonization induces a host response that is different from that induced by single species infection. It is probable that poly-microbial infections were more virulent than single species infections. Thus, poly-microbial infections could modify the clinical course of disease, affecting the selection of antimicrobial therapy and the anticipated response to treatment.
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